期刊文献+

负载冻融抗原的树突状细胞诱导特异性抗膀胱癌作用的研究

Experimental study of specific cytotoxicity induced by dendrtic cells pulsed with tumor lysate towards bladder cancer cell line
下载PDF
导出
摘要 目的研究负载膀胱癌冻融抗原的树突状细胞(DC)诱导的对膀胱癌细胞的特异性杀伤效应。方法反复冻融法获得BIU-87细胞抗原;人单个核细胞在含重组人GM-CSF、IL-4和TNF-α的RPMI1640培养基中体外诱导出人DC并负载肿瘤抗原;9d后成熟DC与自体T细胞共孵育诱导膀胱癌抗原特异性CTLs;用MTT法检测其对BIU-87体外杀伤效应;用ELISA法检测DC分泌IL-12的能力。结果负载膀胱癌抗原的DC诱导的特异性CTLs可明显杀伤BIU-87细胞,在效靶比为40∶1时杀伤率为(65.5±6.4)%,显著高于各对照组(P<0.01);负载抗原DCs较未负载抗原DCs有更强的分泌IL-12能力(P<0.05),而且不同时期的DC分泌的量不同。结论负载膀胱癌抗原的DC在体外可诱导出高效而特异的抗膀胱癌效应,提示以DC为中心的肿瘤生物治疗有望提高膀胱癌综合治疗水平。 Objective To observe specific cytotoxicity induced by dendrtic cells pulsed with bladder tumor lysate towards bladder cancer cell line. Methods BIU-87 ceils (human bladder transitional cell carcinoma cell line) were frozen and melt repeatedly, then tumor lysate was obtained. Human PBMCs were cultured with RPMl1640 contained rhGM-CS+ rhIL-4+ rhTNF-αin vitro, in the meantime pulsed with bladder tumor lysate. In the nineth day matured DCs were harvested, which were then cultured with T Cells, and induced tumor specific CTLs. Specific cytotoxicity caused by the CTLs towards bladder cancer ceils could be detected through MTT technique. DC could also excrete IL-12, which were able to be detected by ELISA technique. Results Tumor specific CTLs induced by DCs pulsed with bladder tumor lysate could kill about (65.5± 6.4)% of BIU-87 cell line when the ratio was 40 : 1, which was significantly stronger than control groups (P〈0. 01). The excreting IL-12 capacity of DCs sensitized by bladder tumor cell antigen was stronger than that of insensitive DCs, and the quantity was different in different stages (P 〈 0. 05). Conclusion DC loaded bladder tumor lysate can induce highly effective and remarkably specific cytotoxicity in vitro, which indicates that anti-tumor biological therapy will be expected to improve the overall therapeutic level of bladder tumor.
出处 《现代泌尿外科杂志》 CAS 2009年第5期340-343,共4页 Journal of Modern Urology
关键词 树突状细胞 膀胱癌 细胞毒性 白介素-12 生物治疗 dendritic cell bladder cancer cytotoxicity IL-12 biological therapy
  • 相关文献

参考文献12

  • 1MOSCA PJ, LYERLY HK, CLAY TM, et al. Dendritic cell vaccines [J]. Front Biosci, 2007, 12(11) :4050-4060.
  • 2HIRSCHOWITZ EA, FOODY T, HIDALGO GE, et al. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells [J]. Lung Cancer, 2007, 57 (3):365- 372.
  • 3THOMAS-KASKEL AK, WALLER CF, SCHULTZE-SEEMANN W, et al. Immunotherapy with dendritic cells for prostate cancer [J]. Int J Cancer, 2007, 121(3) :467-473.
  • 4KIM JH, LEE Y, BAE YS, et al. Phase I / II study of immunotherapy using autologous tumor lysate-pulsed dendritic ceils in patients with metastatic renal cell carcinoma [J].Clin Immunol, 2007, 125(3) :257-267.
  • 5NAIR SK, SNYDER D, ROUSE BT, et al. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts [J]. Int J Cancer, 1997, 70 (6) :706-715.
  • 6王斌,米振国,李志斌,史天良,陈惠庆,宋继文,张雁刚.树突状细胞疫苗对人化荷人膀胱癌SCID鼠循环微转移转归的影响[J].现代泌尿外科杂志,2008,13(4):267-271. 被引量:1
  • 7SCHMITT WE, STASSAR MJ, SCHMITT W, et al. In vitro induction of a bladder cancer-specific T-cell response by mRNA- transfected dendritic cells [J]. J Cancer Res Clin Oncol, 2001, 127(3) :203-206.
  • 8RIBAS A. Genetically modified dendritic cells for cancer immunotherapy [J]. Curt Gene Ther, 2005, 5(6):619-628.
  • 9BANCHEREAU J, PALUCKA AK. Dendritic cells as therapeutic vaccines against cancer [J]. Nat Rev Immunol, 2005, 5 (4) :296-306.
  • 10NESTLE FO, ALUAGIC S, GILLIET M, et al. Vaccination of melanona patients with pepitide-or tumor lysate pulsed dendritic cells[J]. Nat Med, 1998, 4(3) :328-332.

二级参考文献32

  • 1Gubler U, Chua AO, Schoenhaut DS, et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor[ J]. Proc Natl Acad Sci USA, 1991, 15, 88 (10) : 4143 -4147.
  • 2Christoph Holscher. The power of combinatorial immunology: IL-12 and IL-12-related dimerie cytokines in infectious diseases[ J]. Med Microbiol Immunol, 2004, 193( 1 ) : 1 - 17.
  • 3Hoentjen F, Sartor RB, Ozaki M, et al. STAT3 regulate NF-KappaB recruitment to the IL-12p40 promoter in dendritic cells [ J]. Blood, 2005, 105(2) : 689 -696.
  • 4Zhang XY, Zhang HJ, Zhang Y, et al. Identification and expression analysis of alternatively spliced isoforms of human interleukin-23 receptor gene in normal lymphoid cells and selected tumor cells [J ]. Immunogenetics, 2006, 57(12) : 934 -943.
  • 5Niedbala W, Wei XQ, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells[ J]. Eur J Immunol, 2007, 37(11): 3021 -3029.
  • 6Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function [ J ]. Nature, 2007, 450(7169) : 566 -569.
  • 7Beadling C, Slifka MK. Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27 [ J]. Arch Immunol Ther Exp, 2006, 54(1): 15-24.
  • 8Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain[ J ]. Nature, 2003, 421 (6924) : 744 - 748.
  • 9Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions[J]. Nat Rev Immunol, 2005, 5(7) : 521 - 531.
  • 10Laurence A, O 'Shea JJ. T(H)-17 differentiation: of mice and men [ J ]. Nature Immunology, 2007, 8 (9) : 903 - 905.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部